Tarsus Pharmaceuticals, Inc.
67.52-0.04 (-0.06%)
Oct 29, 4:00:00 PM EDT · NasdaqGS · TARS · USD
Key Stats
Market Cap
2.85BP/E (TTM)
-Basic EPS (TTM)
-2.29Dividend Yield
0%Recent Filings
10-Q
Q2 FY2025 results
Tarsus Pharmaceuticals posted strong Q2 FY2025 results, with net product sales from XDEMVY surging 152% year-over-year to $102.7 million, while six-month sales climbed 176% to $181.0 million; yet operating losses narrowed to $22.2 million from $33.3 million a year earlier, thanks to revenue momentum outpacing expense growth. Gross margins held steady around 94%, supported by efficient scaling, though selling, general, and administrative costs rose with marketing push. Diluted EPS improved to $(0.48) from $(0.88), aligning with 42.4 million weighted shares and no anti-dilution effects. Cash swelled to $381.1 million, bolstered by a $134.8 million March offering, against $72.1 million in long-term debt under the 2024 Credit Facility maturing April 2029. XDEMVY now reaches over 90% reimbursement coverage. Still, heavy reliance on a single product leaves room for commercialization hiccups.
8-K
Record $102.7M XDEMVY sales
Tarsus Pharmaceuticals reported record Q2 2025 net product sales of $102.7 million for XDEMVY, up 152% from $40.8 million in 2024, fueled by 91,000 bottles distributed and a DTC campaign that tripled consumer awareness while expanding prescribers by over 30% to more than 20,000. Pipeline progress includes planned Phase 2 starts for TP-04 in ocular rosacea by H2 2025 and TP-05 for Lyme prevention in 2026, with global regulatory meetings on track. Yet net loss narrowed to $20.3 million from $33.3 million. XDEMVY solidifies as Demodex blepharitis standard.
8-K
Tarsus annual meeting results
Tarsus Pharmaceuticals held its annual stockholder meeting on June 12, 2025, where shareholders elected Bobak Azamian and Katherine Goodrich as Class II directors until 2028, despite some withheld votes on Azamian. They approved executive compensation on a non-binding basis and opted for annual say-on-pay votes, while ratifying Ernst & Young as auditors for 2025. Strong turnout signals board stability. No major disruptions noted.
8-K
XDEMVY sales soar 217%
Tarsus Pharmaceuticals reported Q1 2025 net product sales of $78.3 million for XDEMVY, surging 217% year-over-year amid robust demand with 72,000 bottles dispensed. The company bolstered its balance sheet via a $134.8 million equity offering, lifting cash and equivalents to $407.9 million as of March 31. Pipeline advances include a planned Phase 2 trial for TP-04 in ocular rosacea starting H2 2025. Yet net loss narrowed to $25.1 million from $35.7 million last year. Momentum builds.
10-Q
Q1 FY2025 results
Tarsus Pharmaceuticals ramped up XDEMVY sales to $78.3M in Q1 FY2025 ended March 31, 2025, surging 217% year-over-year from $24.7M yet climbing just 18% quarter-over-quarter from Q4 2024, while gross margin held at 93.3% after cost of sales hit $5.2M. Operating loss narrowed to $26.3M from $37.7M a year ago, thanks to revenue momentum offsetting steeper SG&A at $85.0M for commercialization push; net loss eased to $25.1M or $(0.64) per diluted share on 39.3M shares, versus $(1.01) last year, with no material anti-dilution noted. Cash swelled to $408M including marketable securities, bolstered by $134.8M from March 2025 equity offering, against $72.0M long-term debt at 12.3% effective rate maturing 2029. Operating cash burn stood at $20.7M, yielding negative FCF since capex details aren't broken out. Still, reliance on single suppliers for XDEMVY production poses supply risks.
CLSD
Clearside Biomedical, Inc.
3.68-0.22
DRMA
Dermata Therapeutics, Inc.
3.70-0.06
KALA
KALA BIO, Inc.
0.80-0.03
KLRS
Kalaris Therapeutics, Inc.
4.87-0.13
LIANY
LianBio
0.07+0.00
NBY
NovaBay Pharmaceuticals, Inc.
1.20-0.06
PVCT
Provectus Biopharmaceuticals, I
0.07+0.00
SPRY
ARS Pharmaceuticals, Inc.
8.98-0.41
TVRD
Tvardi Therapeutics, Inc.
4.78+0.06
XERS
Xeris Biopharma Holdings, Inc.
9.62+0.39